

This Evidence-to-Decision (EtD) framework addresses **pembrolizumab + chemotherapy** for **cervical cancer with ≥1% PD-L1 expression**.

**QUESTION**

Should immune checkpoint inhibitors vs. alternative regimens be used for adult cervical cancer?	
POPULATION:	adult cervical cancer (CC) with ≥1% PD-L1 expression
INTERVENTION:	immune checkpoint inhibitors (ICIs)
COMPARISON:	alternative regimens
MAIN OUTCOMES:	overall survival; progression-free survival; health-related quality of life; adverse events (CTCAE ≥ 3)
SETTING:	treatment in the palliative 1st line setting
BACKGROUND:	application includes one ICI-based treatment for adult CC with ≥1% PD-L1 expression: <ul style="list-style-type: none"><li>• pembrolizumab + chemotherapy (ESMO-MCBS non-curative score = 4)</li></ul>

## SUMMARY OF JUDGEMENTS

	JUDGEMENT						
PROBLEM	No	Probably no	Probably yes	Yes		Varies	Don't know
DESIRABLE EFFECTS	Trivial	Small	Moderate	Large		Varies	Don't know
REDUCTION IN UNDESIRABLE EFFECTS	Increased harms and toxicity	No/Trivial	Small	Moderate	Large	Varies	Don't know
CERTAINTY OF EVIDENCE	Very low	Low	Moderate	High			No included studies
VALUES	Important uncertainty or variability	Possibly important uncertainty or variability	Probably no important uncertainty or variability	No important uncertainty or variability			
BALANCE OF EFFECTS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	Don't know
RESOURCES REQUIRED	Large costs	Moderate costs	Negligible costs and savings	Moderate savings	Large savings	Varies	Don't know
COST EFFECTIVENESS	Favors the comparison	Probably favors the comparison	Does not favor either the intervention or the comparison	Probably favors the intervention	Favors the intervention	Varies	No included studies
EQUITY	Reduced	Probably reduced	Probably no impact	Probably increased	Increased	Varies	Don't know
ACCEPTABILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
FEASIBILITY	No	Probably no	Probably yes	Yes		Varies	Don't know
AVAILABILITY	Not available in most settings	Probably not available in most settings	Probably available in most settings	Available in most settings		Varies	Don't know

## ASSESSMENT

### Problem

Is the problem a priority?

#### JUDGEMENT

#### RESEARCH EVIDENCE

- No
- Probably no
- Probably yes
- **Yes**
- Varies
- Don't know

An application addressing ICIs for the treatment of 12 adult cancer entities in the palliative 1st line setting has been submitted for consideration by the Expert Committee. This Evidence-to-Decision framework focuses on CC ( $\geq 1\%$  PD-L1 expression), for which one ICI is proposed: pembrolizumab.

The global age-standardized incidence rate of cervix uteri cancer was estimated at 14.1 per 100,000 in 2022, and is among the top 10 cancers in terms of incident cases and causes of cancer-related deaths worldwide (1). The standard of care includes chemotherapy, which has limited benefit for overall survival and is associated with a reduced quality of life in treated patients because of its cytotoxic effects.

### Desirable Effects

How substantial are the desirable anticipated effects?

#### JUDGEMENT

#### RESEARCH EVIDENCE

- Trivial or no
- Small
- Moderate
- **Large**
- Varies
- Don't know

The application presents one randomized trial as evidence for the desirable effects of pembrolizumab + chemotherapy for CC ( $\geq 1\%$  PD-L1 expression) (2-4).

#### Pembrolizumab-based treatment regimens compared to SoC in cervical cancer with PD-L1 $\geq 1\%$ expression

**Patient or population:** cervical cancer with PD-L1  $\geq 1\%$  expression (CPS  $\geq 1$ )

**Intervention:** Pembrolizumab-based treatment regimens

**Comparison:** SoC

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)	Comments
	Risk with SoC	Risk with Pembrolizumab-based treatment regimens				
Overall survival (OS) follow-up: median 39.1 months	At 2 years		HR 0.60 (0.49 to 0.74) [death]	548 (1 RCT) <sup>a</sup>	⊕⊕⊕⊕ High <sup>b,c</sup>	Pembrolizumab-based treatment regimens result in large increases in overall survival. Subsequent ICI exposure upon disease progression in the control arm was not reported.
	39 per 100	57 per 100 (50 to 63)				
	At 3 years					
	27 per 100	46 per 100 (38 to 53)				

	<div> <div>The median OS was <b>16.5</b> months</div> <div>The median OS was <b>11 months more</b> (5.8 more to 17.2 more)</div> </div>					
Progression-free survival (PFS) follow-up: median 39.1 months	<div>At 1 year</div> <div>34 per 100</div>	<div><b>52 per 100</b> (44 to 59)</div>	<div><b>HR 0.60</b> (0.48 to 0.75) [disease progression or death]</div>	548 (1 RCT)	⊕⊕⊕⊕ High <sup>b,c</sup>	Pembrolizumab-based treatment regimens result in increases in progression-free survival.
Global Health Score/Quality of Life (GHS/QoL) assessed with: EORTC-QLQ C30 Scale from: 0 to 100 follow-up: 30 weeks from baseline	The mean global Health Score/Quality of Life was <b>-0.8</b> change score from baseline	MD <b>1.3 change score from baseline higher</b> (3.02 lower to 5.62 higher)	-	519 (1 RCT)	⊕⊕⊕⊕ High <sup>c</sup>	Pembrolizumab-based treatment regimens result in little to no difference in global Health Score/Quality of Life.
<p><b>*The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).  <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>RR:</b> risk ratio</p>						

### Explanations

a. Keynote-826 (NCT03635567)

b. Patient stratification and subgroup analyses according to PD-L1 expression were preplanned therefore, we did not downgrade for risk of selective outcome reporting bias

c. Inconsistency not applicable (single trial only); publication bias not applicable due to prespecified selection process

### Magnitude of effect judgements:

Domain	Judgement per critical outcome		Judgement across desirable critical outcomes
	Overall survival	Health-related quality of life	Overall
Pembrolizumab-containing treatment regimen	Large	Trivial or no	Large

### Additional considerations:

In 2019, the Expert Committee recommended adoption of a threshold for benefit of at least 4-6 months overall survival gain and without detriment to quality of life for cancer medicines or regimens to be considered as candidates for inclusion on the WHO EML (5). Based on this recommendation, the following decision rules were considered in judging the magnitude of effects:

- The outcomes overall survival and health-related quality of life were considered of critical importance to patients with CC – more weight was placed on them in the decision-making process when compared to progression-free survival and adverse events.
- ICIs demonstrating a median overall survival benefit greater than the recommended WHO threshold (i.e. > 4-6 months) would be considered to have a large benefit.
- ICIs demonstrating a median overall survival benefit within the range of the recommended WHO threshold (i.e. between 4 and 6 months) would be considered to have a moderate benefit.
- ICIs demonstrating a median overall survival benefit smaller than the recommended WHO threshold (i.e. < 4-6 months) would be considered to have a small benefit.

	<p>The median overall survival was 11 months more in people treated with the pembrolizumab-containing treatment regimen. The ESMO-MCBS Scorecard reported a score of 4 for the pembrolizumab-containing treatment regimen trial. The magnitude of desirable effects for the outcome overall survival, based on the point estimate, WHO benefit threshold and ESMO-MCBS Scorecard, was judged as large.</p> <p>In terms of health-related quality of life, the pembrolizumab-containing treatment regimen results in no to little difference (high certainty evidence).</p> <p>The overall judgement related to the magnitude of desirable effects cannot be lower than the highest rating across critical outcomes. Therefore, the overall magnitude of desirable effects was judged as large for the pembrolizumab-containing treatment regimen.</p>
--	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Undesirable Effects

How substantial is the **reduction** in undesirable anticipated effects?

JUDGEMENT	RESEARCH EVIDENCE																
<div>○ Increased harms and toxicity</div> <div>Magnitude of reduction in harms and toxicity:</div> <div>○ Trivial or no</div> <div>○ Small</div> <div>○ Moderate</div> <div>○ Large</div> <div>○ Varies</div> <div>○ Don't know</div>	<div>The application presents one randomized trial as evidence for the undesirable effects of pembrolizumab + chemotherapy for CC (≥1% PD-L1 expression) (2-4).</div> <div><div>Pembrolizumab-based treatment regimens compared to SoC in cervical cancer with PD-L1 ≥ 1% expression</div><div><div><div><div><div>Patient or population:</div><div>cervical cancer with PD-L1 ≥ 1% expression (CPS ≥ 1)</div></div><div><div>Intervention:</div><div>Pembrolizumab-based treatment regimens</div></div><div><div>Comparison:</div><div>SoC</div></div></div><table><tr><th rowspan="2">Outcomes</th><th colspan="2">Anticipated absolute effects* (95% CI)</th><th rowspan="2">Relative effect (95% CI)</th><th rowspan="2">Nº of participants (studies)</th><th rowspan="2">Certainty of the evidence (GRADE)</th><th rowspan="2">Comments</th></tr><tr><th>Risk with SoC</th><th>Risk with Pembrolizumab-based treatment regimens</th></tr><tr><td>Adverse events (CTCAE ≥ 3) irrespective of treatment attribution<sup>a</sup></td><td>75 per 100</td><td>82 per 100 (76 to 90)</td><td>RR 1.09 (1.01 to 1.19)</td><td>616 (1 RCT)<sup>b</sup></td><td>⊕⊕⊕○ Moderate<sup>c</sup></td><td>Pembrolizumab-based treatment regimens likely increase adverse events (CTCAE ≥ 3) slightly, irrespective of treatment attribution.</td></tr></table><div><div>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</div><div>CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio</div></div></div></div><div><div>Explanations</div><div><div>a. Adverse events of any cause with an incidence of 20% or more in either treatment group</div><div>b. Keynote-826 (NCT03635567)</div><div>c. Adverse events were only reported if occurring in &gt; 10% or &gt; 20% of trial participants, potentially not accounting for rare but serious adverse events; thus, we downgraded for indirectness</div></div><div><div>Additional considerations:</div><div>Moderate certainty evidence showed that the pembrolizumab-containing treatment regimen probably increases adverse events slightly when compared to standard of care.</div></div></div></div>	Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)	Comments	Risk with SoC	Risk with Pembrolizumab-based treatment regimens	Adverse events (CTCAE ≥ 3) irrespective of treatment attribution <sup>a</sup>	75 per 100	82 per 100 (76 to 90)	RR 1.09 (1.01 to 1.19)	616 (1 RCT) <sup>b</sup>	⊕⊕⊕○ Moderate <sup>c</sup>	Pembrolizumab-based treatment regimens likely increase adverse events (CTCAE ≥ 3) slightly, irrespective of treatment attribution.
	Outcomes		Anticipated absolute effects* (95% CI)						Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)	Comments					
		Risk with SoC	Risk with Pembrolizumab-based treatment regimens														
	Adverse events (CTCAE ≥ 3) irrespective of treatment attribution <sup>a</sup>	75 per 100	82 per 100 (76 to 90)	RR 1.09 (1.01 to 1.19)	616 (1 RCT) <sup>b</sup>	⊕⊕⊕○ Moderate <sup>c</sup>	Pembrolizumab-based treatment regimens likely increase adverse events (CTCAE ≥ 3) slightly, irrespective of treatment attribution.										

## Certainty of evidence

## What is the overall certainty of the evidence of effects?

JUDGEMENT	RESEARCH EVIDENCE				
○ Very low ○ Low ○ <b>Moderate</b> ○ High ○ No included studies	Domain	Judgement per critical outcome			Judgement across critical outcomes
	ICIs	Overall survival	Health-related quality of life	Adverse events	Overall
	Pembrolizumab-containing treatment regimens	High	High	Moderate	Moderate
	<b>Additional considerations:</b>				
	Across the critical outcomes, the lowest certainty of evidence rating was moderate for the pembrolizumab-containing treatment regimen.				

## Values

Is there important uncertainty about or variability in how much people value the main outcomes?

JUDGEMENT	RESEARCH EVIDENCE									
<div>○ Important uncertainty or variability</div> <div>○ Possibly important uncertainty or variability</div> <div>○ Probably no important uncertainty or variability</div> <div>○ No important uncertainty or variability</div>	<p>A systematic review of qualitative research identified 17 studies published between 2017 and 2022 that addressed the experience of patients considering or using checkpoint inhibitors in cancer (6). Overall, patients viewed immune checkpoint inhibitors positively when compared to other anti-cancer treatments, noting newfound hope, fewer or more manageable treatment-related side effects, and among those experiencing treatment success, improved quality of life when compared to chemotherapy and radiation therapy. In some cases, patients were uncertain about response durability long-term and checkpoint inhibitor-specific adverse events. Patient concerns around checkpoint inhibitors may be mitigated, at least in part, by positive patient-practitioner relationships and support from other patients with lived checkpoint inhibitor experience by way of community groups. Further, fatigue is a common checkpoint inhibitor-specific adverse event. Implementing supportive care programs can help patients undergoing checkpoint inhibitor treatment cope with fatigue and maximize their quality of life.</p> <p>It was noted that most studies included in this systematic review omitted patients that discontinued checkpoint inhibitor treatment due to serious adverse events or failed to respond to checkpoint inhibitor treatment limiting our understanding of patient experiences with checkpoint inhibitors in this regard.</p> <table><tr><th colspan="3">Importance of uncertainty and variability of how people value outcomes</th></tr><tr><th>ICIs</th><th>Net balance</th><th>Judgement</th></tr><tr><td>Pembrolizumab-containing treatment regimens</td><td>Large net desirable</td><td>No important uncertainty or variability</td></tr></table> <p><b>Additional considerations:</b></p> <p>A judgement was made that how much people value the main outcomes, including overall survival, lies on a spectrum, and depends on the magnitude of benefit and harm from treatment. In a situation with trivial benefit and large harm, it was inferred that most people would not choose to pursue treatment if available. In</p>	Importance of uncertainty and variability of how people value outcomes			ICIs	Net balance	Judgement	Pembrolizumab-containing treatment regimens	Large net desirable	No important uncertainty or variability
Importance of uncertainty and variability of how people value outcomes										
ICIs	Net balance	Judgement								
Pembrolizumab-containing treatment regimens	Large net desirable	No important uncertainty or variability								

	<p>a situation with large benefit and trivial harm, it was inferred that all or almost all people would choose to pursue treatment if available.</p> <p>Pembrolizumab-containing treatment regimens result in a large increase in OS (11 months), have trivial to no effect on health-related quality of life and probably increase adverse events when compared to standard of care. Based on this and the ESMO-MCBS Scorecard, it was judged that pembrolizumab-containing treatment regimens offer a large net desirable effect and people would have no important uncertainty or variability in how much they value the main outcomes, particularly preferring avoiding premature death.</p>
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

## Balance of effects

Does the balance between desirable and undesirable effects favor the intervention or the comparison?

JUDGEMENT	RESEARCH EVIDENCE														
<div>○ Favors the comparison</div> <div>○ Probably favors the comparison</div> <div>○ Does not favor either the intervention or the comparison</div> <div>○ Probably favors the intervention</div> <div>○ <b>Favors the intervention</b></div> <div>○ Varies</div> <div>○ Don't know</div>	<table><tr><th>ICIs</th><th>Net balance</th><th>Values</th><th>Certainty of evidence</th><th>Balance of effects</th></tr><tr><td>Pembrolizumab-containing treatment regimens</td><td>Large net desirable</td><td>No important uncertainty or variability</td><td>Moderate</td><td>Favors the intervention</td></tr></table>					ICIs	Net balance	Values	Certainty of evidence	Balance of effects	Pembrolizumab-containing treatment regimens	Large net desirable	No important uncertainty or variability	Moderate	Favors the intervention
	ICIs	Net balance	Values	Certainty of evidence	Balance of effects										
Pembrolizumab-containing treatment regimens	Large net desirable	No important uncertainty or variability	Moderate	Favors the intervention											
<div><b>Additional considerations:</b></div> <div>A judgement based on the net balance between desirable and undesirable effects, patient values and the certainty of evidence was made that the balance of effects favors pembrolizumab-containing treatment regimens.</div>															

## Resources required


How large are the resource requirements?

JUDGEMENT	RESEARCH EVIDENCE			
○ Large costs ○ Moderate costs ○ Negligible	Median wholesale unit price (USD) for pembrolizumab concentrate (100 mg vial) across World Bank income levels*:			
	Income level	Median	IQR	Sample size based on number of countries
	HIC	3452.61	2692.68 to 3871.57	34

costs and savings

- o Moderate savings
- o Large savings
- o Varies
- o Don't know

UMIC	2862.25	2693.96 to 3299.45	11
LMIC	1759.42	259.34 to 2343.91	3




Source: author derived calculation based on most recent available wholesale prices (as of November 2024) extracted from GlobalData Price Intelligenc (POLI) and Eversana NAVLIN Price & Access datasets. Latest publicly available country-specific prices may be accessed via sources listed here, where available: <https://www.who.int/teams/health-product-and-policy-standards/medicines-selection-ip-and-affordability/affordability-pricing/med-price-info-source>

Median retail unit price (USD) for pembrolizumab concentrate (100 mg vial) across World Bank income levels\*:

Income level	Median	IQR	Sample size based on number of countries
HIC	3773.16	2928.38 to 4377.63	35
UMIC	3452.32	3027.62 to 4001.05	12
LMIC	2345.89	265.67 to 2812.69	3





Source: author derived calculation based on most recent available retail prices (as of November 2024) extracted from GlobalData Price Intelligence (POLI) and Eversana NAVLIN Price & Access datasets. Latest publicly available country-specific prices may be accessed via sources listed here, where available: <https://www.who.int/teams/health-product-and-policy-standards/medicines-selection-ip-and-affordability/affordability-pricing/med-price-info-source>

### Additional considerations:

Direct evidence addressing the unit price for pembrolizumab was available.

Relative to other EML medicines, the costs of pembrolizumab at the current unit pricing are large across World Bank income levels. It was noted that country costs for pembrolizumab correlate with income level, with the highest median wholesale and retail prices observed in high-income countries. Further, within an income level, there was substantial variation in prices which can be in part attributed to pricing dynamics at the country level and the limited number of countries informing each income level. These small sample sizes reduce our confidence in the estimates, especially for LMICs for which data from only three countries were available. Further, there were no data available for LICs.

Nonetheless, harnessing pricing dynamics is needed to promote implementation and affordable use of pembrolizumab at the country level. Of note, biosimilar entry for pembrolizumab is anticipated in the next 3 to 5 years (2028 to 2023). Given its dominant role in several critical indications, it likely has the largest potential for cost reduction (7).

## Does the cost-effectiveness of the intervention favor the intervention or the comparison?

### JUDGEMENT

○ Favors the comparison  
 ○ Probably favors the comparison  
 ○ Does not favor either the intervention or the comparison  
 ○ Probably favors the intervention  
 ○ Favors the intervention  
 ○ **Varies**  
 ○ No included studies

### RESEARCH EVIDENCE

Evidence addressing cost-effectiveness of pembrolizumab plus chemotherapy for the first-line treatment of patients with metastatic CC was available from select countries, including China (UMIC) (8) and the United States (HIC) (9).

Country	Income level	WTP threshold	ICER	Cost-effective?
United States	HIC	USD 150,000 / QALY	USD 58,446 per QALY	Yes
China	UMIC	USD 35,269 / QALY	USD 52,765 per QALY*	No

\*Pembrolizumab acquired at 41% of its original price via charitable donation policy offered by Merck Sharp & Dohme Corp. Original ICER = USD 114,275 per QALY.

Empirical evidence estimating cost-effective thresholds based on health expenditures per capita and life expectancy at birth was available for 174 countries (10). As of 2019, the following cost-effectiveness thresholds in USD per QALY were estimated for each country income level. The authors noted that their empirically derived thresholds were lower than those used in many countries. If used, they may result in more conservative health decision-making.

Income level	Range	Median	IQR	Sample size based on number of countries	Cost-effective?
HIC	\$5480–\$95958	\$18,218	\$10229–\$43175	54	Varies
UMIC	\$1108–\$10638	\$4,355	\$2886–\$5301	48	No
LMIC	\$190–\$3249	\$745	\$451–\$1389	49	No
LIC	\$87–\$320	\$163	\$131–\$229	23	No

To help achieve cost-effective use of pembrolizumab across World Bank income settings without compromising efficacy and safety, alternative dosing strategies have been proposed (11). They include electronic rounding, hybrid dosing, lower dose selection, interval extension and shortening of treatment duration. The scientific basis for these alternative dosing strategies is growing and is based on evidence from both clinical trials and pharmacokinetic studies.

#### Additional considerations:

In the absence of a *de novo* cost-effectiveness model that considers diverse income settings and alternative dosing strategies, a judgement on the cost-effectiveness was made based on select examples and empirically derived cost-effective thresholds.


While the checkpoint inhibitor under consideration for CC had desirable effects, at the current price, it is likely not cost-effective in most settings, particularly in LMICs and LICs, and when diagnostic requirements are considered.

Clinically proven alternative dosing strategies may be an important step in helping achieve cost-effective use of checkpoint inhibitors in more settings.

### Equity

What would be the impact on health equity?

JUDGEMENT	RESEARCH EVIDENCE
<p><b>○ Reduced</b></p> <p>○ Probably reduced</p> <p>○ Probably no impact</p> <p>○ Probably increased</p> <p>○ Increased</p> <p>○ Varies</p> <p>○ Don't know</p>	<p><b>Additional considerations:</b></p> <p>Despite checkpoint inhibitors being accessible in many HICs, the WHO EML is a global list and the impact on LMICs and LICs was considered.</p> <p>Because the ICI under consideration offers large desirable benefits but is not accessible to patients globally because of its prohibitively high price, a judgement was made that health equity would be reduced.</p> <p>Sub-Saharan Africa, where the prevalence of HIV is high, is disproportionately burdened by cervical cancer. Real world evidence found no statistically significant difference in PD-L1 expression between squamous cervical carcinomas of Mozambican women living with and without HIV (12). Therefore, women living with HIV could benefit from pembrolizumab and future studies in HIV endemic settings could confirm the therapeutic effects of pembrolizumab in this immunocompromised population. Finally, the safety of immune checkpoint inhibitor use in people living with HIV where there is viral suppression through antiretroviral therapy has been demonstrated.</p> <p>Therefore, if price decreased substantially, access for disadvantaged populations and women living with HIV would improve and health equity would increase.</p>
<b>Acceptability</b> Is the intervention acceptable to key stakeholders?	
JUDGEMENT	RESEARCH EVIDENCE
<p>○ No</p> <p>○ Probably no</p> <p>○ Probably yes</p> <p>○ Yes</p> <p><b>○ Varies</b></p> <p>○ Don't know</p>	<p>A systematic review of qualitative research identified 17 studies published between 2017 and 2022 that addressed the experience of patients considering or using checkpoint inhibitors in cancer (6). Overall, patients viewed immune checkpoint inhibitors positively when compared to other anti-cancer treatments, noting newfound hope, fewer or more manageable treatment-related side effects, and among those experiencing treatment success, improved quality of life when compared to chemotherapy and radiation therapy. Of note, hope is key for cancer patient acceptance of further treatment and is associated with improved symptom burden and quality of life and decreased psychological distress.</p> <p><b>Additional considerations:</b></p> <p>Empiric evidence from the patient perspective provides support for the acceptability of immune checkpoint inhibitors.</p> <p>Immune checkpoint inhibitors are likely not acceptable to most health decision makers and health systems, especially those in LMICs and LICs, due to cost. The large cost of pembrolizumab when compared to other anti-cancer treatments risk diverting resources from health budgets at the expense of other essential medicines.</p>
<b>Feasibility</b> Is the intervention feasible to implement?	
JUDGEMENT	RESEARCH EVIDENCE
<p>○ No</p> <p>○ Probably</p>	<p>Diagnostic requirements – immunohistochemistry companion tests – to identify patients with the indication approved for treatment.</p>

<p>no</p> <p>o Probably yes</p> <p>o Yes</p> <p>o <b>Varies</b></p> <p>o Don't know</p>	<p>The WHO Essential Diagnostics List includes a basic panel for immunohistochemical (IHC) markers for diagnosis of solid tumors, but the panel does not include IHC testing markers for PDL1 (13).</p> <div data-bbox="252 191 1356 406"> <p><b>Basic immunohistochemical (IHC) panel for diagnosis of solid tumours</b> </p> <p>Basic panel of immunohistochemical (IHC) markers for diagnosis of solid tumours</p> <table border="1"> <thead> <tr> <th>Cancer</th><th>Diagnostic tests</th></tr> </thead> <tbody> <tr> <td>Facility level</td><td></td></tr> <tr> <td>Laboratory</td><td>IHC testing markers include desmin, cytokeratin, AE1/AE3, S100, synaptophysin, myogenin, hCG, PLAP, Oct3/4, NANOG, CD30, CD117/c-kit, WT1, SALL4</td></tr> </tbody> </table> </div> <p>Additional considerations for healthcare-worker training, resources for the management of side-effects and monitoring capabilities.</p> <p><b>Additional considerations:</b></p> <p>The interventions are already implemented in many high-income settings. Beyond the large cost, another barrier to implementation is the need for diagnostic companion tests. Immunohistochemistry is an important component of the application of pembrolizumab treatment in CC.</p>	Cancer	Diagnostic tests	Facility level		Laboratory	IHC testing markers include desmin, cytokeratin, AE1/AE3, S100, synaptophysin, myogenin, hCG, PLAP, Oct3/4, NANOG, CD30, CD117/c-kit, WT1, SALL4
Cancer	Diagnostic tests						
Facility level							
Laboratory	IHC testing markers include desmin, cytokeratin, AE1/AE3, S100, synaptophysin, myogenin, hCG, PLAP, Oct3/4, NANOG, CD30, CD117/c-kit, WT1, SALL4						

## Availability

What is the regulatory status, market availability and on-the-ground availability/access of the medicine to patients?

JUDGEMENT	RESEARCH EVIDENCE
<p>o Not available in most settings</p> <p>o <b>Probably not available in most settings</b></p> <p>o Probably available in most settings</p> <p>o Available in most settings</p> <p>o Varies</p> <p>o Don't know</p>	<p>Pembrolizumab is approved for use in 85 countries worldwide – mainly high-income countries including Canada, the United States, European Union member countries and Japan (14).</p> <p>Data on the availability, out-of-pocket costs, and accessibility of pembrolizumab for melanoma, non-small cell lung cancer, colorectal cancer and renal cell carcinoma were available from the 2023 update to the ESMO Global Consortium Study (15). In HICs, pembrolizumab for melanoma was “almost always available to patients at no cost or on a subsidized basis”. In LMICs and LICs, when available, however, pembrolizumab was “generally provided only at full cost as an out-of-pocket expenditure for patients”. Although pembrolizumab for melanoma was almost always actually available in HICs (accessibility with a valid prescription), there was important variation in the actual availability across UMICs, LMICs and LICs. Outside of HICs, pembrolizumab for non-small cell lung cancer, colorectal cancer and renal cell carcinoma was more commonly provided as an out-of-pocket expenditure for patients than not – often at full cost to the patient. These data provide indirect evidence regarding the extent of pembrolizumab availability for cervical cancer across World Bank income settings.</p> <p><b>Additional considerations:</b></p> <p>Pembrolizumab is approved for use in many countries; however, on-the-ground access outside of HICs is limited.</p>

## REFERENCES

1. Globocan. Age-Standardized Rate (World) per 100 000, Incidence and Mortality, Both Sexes, in 2022 2022 [Available from: [https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group\\_populations=1&types=0\\_1&sort\\_by=value1](https://gco.iarc.fr/today/en/dataviz/bars?mode=cancer&group_populations=1&types=0_1&sort_by=value1).
2. Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. 2021;385(20):1856-67.
3. Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: final Overall Survival Results of KEYNOTE-826. 2023;41(36):5505-11.
4. Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. 2023;24(4):392-402.
5. Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, et al. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. The Lancet Global Health. 2022;10(12):e1860-e6.
6. Yip R, Arnolda G, Lamprell K, Nic Giolla Easpaig B, Chittajallu R, Delaney G, et al. Experience of patients considering or using checkpoint inhibitors in cancer treatment: a systematic review of qualitative research. J Immunother Cancer. 2024;12(1).
7. Schouten A. Addressing the Financial Implications of PD-1/PD-L1 Immune Checkpoint Inhibitors: A Policy Analysis of Access and Inclusion on the WHO Model List of Essential Medicines 2025 [Available from: [https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/addition-of-new-medicines/a.22-pd1-pdl1-icis\\_financial-impact-report.pdf?sfvrsn=7378e942\\_1](https://cdn.who.int/media/docs/default-source/2025-eml-expert-committee/addition-of-new-medicines/a.22-pd1-pdl1-icis_financial-impact-report.pdf?sfvrsn=7378e942_1).
8. Urrego-Reyes J, Lopez C, Marrugo A C, Velasco JS, Singla P, Gotarkar S, et al. EE84 Cost-Effectiveness of Pembrolizumab Plus Nab-paclitaxel in Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) Whose Tumors Expressed Pd-L1 (CPS &#x2265;10) in Colombia. Value in Health. 2023;26(6):S74-S5.
9. Monk BJ, van Mens S, Hale O, Boer J, van Hees F, Swami S, et al. Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States. Oncology and Therapy. 2024.
10. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11.
11. Malmberg R, Zietse M, Dumoulin DW, Hendriks JJMA, Aerts JGJV, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. The Lancet Oncology. 2022;23(12):e552-e61.
12. Lovane L, Tulsidas S, Carrilho C, Karlsson C. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV. Scientific Reports. 2024;14(1):12974.
13. World Health Organization. WHO Model List of Essential In Vitro Diagnostics 2024 [Available from: <https://edl.who.healthtechnologies.org/>.
14. CPP Investments. CPPIB Acquires Partial Royalty Interest in KEYTRUDA® (pembrolizumab) from LifeArc 2019 [Available from: <https://www.cppinvestments.com/newsroom/cppib-acquires-partial-royalty-interest-keytruda-pembrolizumab-lifearc/>.
15. Cherny NI, Trapani D, Galotti M, Saar M, Bricalli G, Roitberg F, et al. ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update. Ann Oncol. 2025;36(3):247-62.